Press review
Media
Press articles and media passages dealing with cases of meningiomas linked to Androcur, Lutéran, Lotényl, of testimonies and actions in justices of the victims, of scientific publications.
December 21, 2024
News
Media
Help scandal on the progestogen Androcur: Emmanuelle recounts her "trying but essential" fight
November 24, 2024
News
Legal procedures
Media
Androcur: Amavea files a complaint against X for endangering others and aggravated deception
Press contact
Emmanuelle Huet-Mignaton
contact@amavea.org
06 07 58 67 96
The press kit is available for free download.
-
Lotényl and Lotéran, two contraceptive pills in the viewfinder of the authorities for risk of meningioma
Lire la suiteLutényl and Lutéran, two contraceptive pills under scrutiny by authorities for risks of…
: Lutényl et Lutéran, deux pilules contraceptives dans le viseur des autorités pour des risques de méningiome -
“Because of the Androcur, I had five brain tumors. I have four left. »»
Lire la suitehttps://www.nouvelobs.com/vie-de-malade/20200923.OBS33724/a-cause-de-l-androcur-j-ai-eu-cinq-tumeurs-au-cerveau-il-m-en-reste-quatre.html LIFE OF A SICK PERSON. Emmanuelle Mignaton took this progestin for years to treat…
: « A cause de l’Androcur, j’ai eu cinq tumeurs au cerveau. Il m’en reste quatre. » -
Menopause, endometriosis…. Alert on the risk of meningiom of lutenyl and luteran
Lire la suiteThe French National Agency for Medicines and Health Products Safety (ANSM) is launching a public consultation on the conditions of use for women…
: Ménopause, endométriose…. Alerte sur le risque de méningiome du Lutényl et du Lutéran -
20 minutes: "Women who have taken luteran or lutenyl must verify that they have no neurological symptoms", explains Isabelle Yoldjian, of ANSM
Lire la suiteINTERVIEW The National Agency for the Safety of Medicines has launched a call for applications, running until the end of September…
: 20 minutes : « Les femmes qui ont pris du Lutéran ou du Lutényl doivent vérifier qu’elles n’ont pas de symptômes neurologiques », explique Isabelle Yoldjian, de l’ANSM
